MedTrace Logo

Glycocalyx Biomarkers in ARDS for Clinical Prognosis and Pulmonary Fibrosis

NCT03854565 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 336

Last updated 2019-02-26

No results posted yet for this study

Summary

ARDS is a severe disease in ICU, and could induce high mortality. Glycocalyx is an important matrix construction which covers endothelial cells, it could protect endothelial cells injury and the glycocalyx biomarkers could predict pulmonary injury.

Decorin is a member of the small leucine-rich proteoglycan (SLRP) family, contains a single glycosaminoglycan (GAG) chain and a core protein with 12 leucine-rich repeats. In the previous study, decorin is associated with cardiac and liver fibrosis, however, the effects of decorin on ARDS pulmonary fibrosis have not been clarified.

Conditions

  • ARDS, Human
  • Endothelial Dysfunction
  • Mechanical Ventilation Pressure High

Interventions

DIAGNOSTIC_TEST

Glycocalyx measurement，respiratory mechanics measurement

ELASA measure glycocalyx, measure plateau pressure, driving pressure

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Principal Investigators

  • Chun C Pan, Dr · Zhongda hospital, Southeast University, Jiangsu, China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03854565 on ClinicalTrials.gov